Sort
21,453 grants matching “tuberculosis”
Influence of SIV replication on TB progression and immunity
$933,104Zandrea Ambrose · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · AI
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$932,733Vanderbilt University · U01 · FY2001 · AI
Odorprint Based Disease Diagnostics
$932,693Dmitry Rinberg · New York University School Of Medicine · R01 · FY2025 · DC
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
$932,592University Of Texas Sw Med Ctr/Dallas · U01 · FY2001 · AI
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
$932,430Ann R Falsey · University Of Rochester · UM1 · FY2024 · AI
Innovative Strategies to Improve Tuberculosis Diagnostics in Children
$932,090Molly Forrest Franke · Harvard Medical School · U19 · FY2015 · AI
Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection
$931,829Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2025 · AI
Odorprint Based Disease Diagnostics
$931,815Dmitry Rinberg · New York University School Of Medicine · R01 · FY2023 · DC
New anti-tubercular agents targeting intracellular bacteria
$931,143Tanya Parish · Seattle Children'S Hospital · R01 · FY2025 · AI
Bacterial and host determinants of progression, manifestations and consequences of TB
$930,827Reynaldo Dietze · Rutgers Biomedical And Health Sciences · U19 · FY2023 · AI
Undetected Drug resistance and Tolerance in lesions of recurrent TB
$930,462Faramarz Valafar · San Diego State University · R01 · FY2025 · AI
Clinical Trial Site Monitoring for PHOENIx MDR-TB
$929,916Kimberly Smith · Ppd Development Lp · N01 · FY2023 · AI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)
$929,089C Robert Horsburgh · Boston University Medical Campus · R01 · FY2020 · AI
Disease Modifying Biologics for Rheumatoid Arthritis
$929,079Rekha Bansal · Novelmed Therapeutics, Inc. · R44 · FY2011 · AG
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination
$928,224Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2023 · AI
A systems approach to manipulate microbial adaptation to structured environments
$927,560Nitin S Baliga · Institute For Systems Biology · R01 · FY2019 · AI
Innate Determinants of Microbial Immunity
$926,909Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)
$926,757Karen R Jacobson · Boston Medical Center · R01 · FY2023 · AI
The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis
$926,013John R. Chan · Albert Einstein College Of Medicine · R01 · FY2020 · AI
Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.
$925,915Kathleen Powis · Massachusetts General Hospital · R01 · FY2022 · AI
International Research in Thailand
$925,647Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Rituximab for Anticytokine Autoantibody-Associated Syndromes
$925,647Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
$924,745Neil Desai · Aadi, Llc · R42 · FY2015 · CA
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active
$924,431Padmini Salgame · Boston Medical Center · U19 · FY2017 · AI
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)
$923,533Kevin Urdahl · Seattle Children'S Hospital · N01 · FY2022 · AI